Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Active area of investment (1:13)
- Baxter BioPharma Solutions (1:25)
- PCI Pharma Services (2:07)
- Alcami (3:22)
- Catalent (4:31)
- Vetter (5:47)
- Thermo Fisher Scientific (6:41)
- Grand River Aseptic Manufacturing (7:35)
- Lonza (9:12)
- Curia (9:50)
- Jubilant HollisterStier (10:22)
- Carbogen Amcis (10:53)
- Fareva (11:46)
- BSP Pharmaceuticals (12:43)
- Recipharm (13:33)
- Aenova (15:01)
- Wuxi Biologics (15:42)
- Samsung Biologics (16:08)
- Ajinomoto Bio-Pharma Services (16:44)
- Selkirk Pharma (17:07)
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show
